DDW Highlights: 14 April 2026

The Oxford‑Crick team revealed that mutations in the non‑coding RNU4‑2 gene drive two separate recessive neurodevelopmental disorders. By applying saturation genome editing, researchers evaluated more than 500 variants, producing a functional map that links specific DNA changes to disease severity. This high‑resolution atlas enables clinicians to diagnose affected children within months rather than years, and it opens a pathway for therapies that modulate RNU4‑2 RNA levels. The work demonstrates how systematic testing of non‑coding regions can uncover hidden disease mechanisms and accelerate precision diagnostics across the genome.

A first‑in‑human CAR‑T cell trial now targets hard‑to‑treat solid tumours in 60 children across the UK and US. Led by the NextTGen consortium under Cancer Grand Challenges, the study evaluates personalised T‑cell products designed to recognise paediatric tumour antigens that differ from adult cancers. Researchers hope the approach will improve survival while sparing young patients from the long‑term toxicities of conventional chemotherapy, such as infertility and cognitive deficits.

If successful, the trial could redefine standard care for paediatric solid tumours, a disease area where survival rates have stagnated for three decades. The FDA’s recent approval of Eli Lilly’s oral GLP‑1 pill, Foundio, adds a flexible obesity therapy that achieved an average 27‑lb (≈$31) weight loss at the highest dose, alongside reductions in cholesterol, triglycerides and blood pressure. 1 billion, underscoring the company’s push into neurodegenerative disease treatment. In parallel, Altsian dosed the first patient with ALZ‑507, an oral Alzheimer’s candidate that targets amyloid oligomers and corrects APOE4 effects, highlighting a broader trend toward precision, disease‑modifying therapies.